For years, the promise of GLP-1 weight loss treatment came with a catch: a weekly injection. Now, for the millions of Americans who would rather skip the needle entirely, two oral alternatives are on the market, and doctors say demand is real.
Novo Nordisk’s oral Wegovy has been available since January 2026. Eli Lilly’s newly approved Foundayo began shipping this week. Seven obesity specialists around the country paint a clear picture of how these pills are being received and what it means for the rapidly expanding weight loss drug market, which is projected to exceed $100 billion annually within the next decade.
The doctors were unanimous: a meaningful share of patients had simply been unwilling to self-inject, and that group is now showing up in clinics asking about pills. Dr. Christina Nguyen, an obesity and family medicine physician in Atlanta, put it plainly: one patient told her they would rather stay overweight than ever use a needle. Beyond needle aversion, pills offer practical advantages. They do not require refrigeration, they are more discreet, and they fit more naturally into daily routines. All seven doctors said they had started prescribing oral Wegovy, and three reported that pills now account for roughly 10% of their patient caseload. Most of those patients are first-time GLP-1 users rather than people switching from injectables.
Both pills carry a self-pay starting price of $149 per month for the lowest dose, undercutting injectable Wegovy ($349/month) and Zepbound ($299/month) significantly. But the two oral drugs differ in one important practical way. Oral Wegovy must be taken on an empty stomach with only a small sip of water, at least 30 minutes before any food, drink, or other medication. Foundayo has no such restrictions and can be taken at any time of day. That flexibility could be decisive. Dr. Nguyen said that if Foundayo is competitively priced, most patients will likely prefer it.
In clinical trials, oral Wegovy produced roughly a 14% reduction in body weight over 64 weeks, while Foundayo produced about an 11% reduction over 72 weeks. Injectable Zepbound, by comparison, has shown reductions of 20% or more, making it the preferred option for patients with severe obesity or more complex medical cases. Doctors are also not rushing to switch patients who are already doing well on injectables.
One open question surrounds long-term health benefits. Semaglutide, the active ingredient in both injectable and oral Wegovy, has shown benefits beyond weight loss in trials, including reduced cardiovascular risk. Foundayo uses a different molecule entirely, orforglipron, and some doctors are cautious about assuming it will carry the same broader advantages. Lilly says it is still studying the drug and that many participants in its clinical trial showed some improvement in cardiovascular risk markers.
Even at $149 a month, weight loss drugs remain out of reach for many Americans. Insurance coverage for GLP-1 medications has become increasingly restricted, and doctors say they spend significant time helping patients figure out how to afford treatment. Dr. Catherine Varney of the University of Virginia School of Medicine said she feels more like a financial planner these days than a physician. When insurance does cover these drugs, out-of-pocket costs can fall to as little as $25 to $50 per month, but without coverage even the cheaper pill options are a stretch for much of the population. As Varney noted, this is still largely a market for upper-middle-class patients and above.
Whether oral GLP-1 drugs can genuinely expand access to treatment, or simply add another tier to an already stratified system, may be the defining question of this next chapter in the obesity medicine story.